PATENT CLAIM ANALYSIS

Application Number: 15764150
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "089000"]

Abstract:
Embodiments of the present disclosure pertain to methods of inhibiting cancer cells by exposing the cancer cells to a purinergic receptor antagonist that targets one or more purinergic receptors of the cancer cells. The targeted purinergic receptors can include P2 purinergic receptors, such as P2X purinergic receptor subtypes (e.g., P2X3 or P2X5) and P2Y purinergic receptor subtypes (e.g., P2Y2). In some embodiments, the inhibited cancer cells are associated with hepatocellular carcinoma. In additional embodiments, the present disclosure pertains to methods of treating hepatocellular carcinoma in a subject by administering a purinergic receptor antagonist to the subject such that the antagonist targets one or more purinergic receptors of hepatocellular carcinoma cells in the subject. In some embodiments, the subject is a human being suffering from hepatocellular carcinoma.

Claim (Index 24):
The method of  claim 1 , wherein the exposing kills the cancer cells.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 90.0
- Lexical Diversity: 2.27419
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15312252', '11054919', '15998556', '14412571', '14991513']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.786771269528474
- 35 USC 102 Novelty (BERT): 0.5052912481498019
- Combined Prediction Score: 0.7586232673906068
- Mean Citation Score: 252.010362
- Max Citation Score: 280.0174
- Similarity Product: 222.61011572799683

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test